Clinical Trial Update: Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cediranib alone or with gefitinib in recurrent or progressive glioblastoma was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Cediranib (Cediranib)
• Gefitinib (Gefitinib)

Snippet

Sponsor: University College, London | Conditions: Glioblastoma | Phase 2 | Status: TERMINATED | Results posted: 2017-01-27